Plant Name: Platycodon grandiforus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADRA2B; HCAR2; | |
| GAA; | |
| GLA; RECQL; GLO1; NOX4; ALOX12; AKR1B1; HSD17B10; ALOX15; ALDH1A1; TNKS; PARP1; TNKS2; POLB; CD38; | |
| GSK3B; FLT3; MAPK1; CDK8; CDK9; | |
| CA2; CA12; CA9; CA3; CA7; CA4; | |
| PPARA; PPARD; | |
| NR1H4; | |
| ALOX5; MAOA; XDH; | |
| KDM4E; | |
| MMP9; MMP12; MMP2; | |
| TLR2; | |
| HIF1A; TP53; NFKB1; | |
| ABCG2; | |
| LMNA; NPC1; RAB9A; FABP3; FABP5; FABP2; FABP4; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.771E-12 | 1.027E-08 | CA12, CA2, CA3, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.613E-11 | 6.967E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.187E-11 | 7.114E-08 | ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.071E-11 | 8.230E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.344E-09 | 7.502E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.394E-09 | 7.590E-07 | CA12, CA2, CA3, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.878E-09 | 1.442E-06 | CA12, CA2, CA3, CA4, CA7, CA9, GLO1, MMP12, MMP2, MMP9, NR1H4, PARP1, PPARA, PPARD, TNKS, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.955E-09 | 2.158E-06 | CA12, CA2, CA3, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.200E-09 | 2.158E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.583E-08 | 1.182E-05 | CA2, CA7, HCAR2, HIF1A, MAPK1, NPC1, NR1H4, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.371E-08 | 1.380E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.196E-07 | 3.255E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.542E-07 | 4.045E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.444E-07 | 6.047E-05 | CA2, CA7, CD38, HCAR2, HIF1A, MAPK1, NPC1, NR1H4, PARP1, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.619E-07 | 1.551E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.083E-06 | 2.125E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.657E-06 | 4.285E-04 | ALOX12, ALOX15, ALOX5, TLR2 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.460E-06 | 9.441E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.810E-06 | 1.287E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.810E-06 | 1.287E-03 | ALOX12, ALOX15 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 9.587E-06 | 1.287E-03 | ABCG2, AKR1B1, APP, CA4, CD38, CDK8, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, FABP4, FLT3, GAA, GLA, GLO1, GSK3B, HIF1A, HSD17B10, KDM4E, LMNA, MAOA, MAPK1, MMP12, MMP2, NFKB1, NOX4, NPC1, PARP1, POLB, PPARA, PPARD, RAB9A, RECQL, SMN1, SMN2, TLR2, TNKS, TNKS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.261E-05 | 1.625E-03 | AKR1B1, ALOX12, CD38, GLO1, GSK3B, HIF1A, LMNA, MMP9, NFKB1, NR1H4, PPARD, TP53 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.397E-05 | 1.779E-03 | APP, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, NPC1 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.516E-05 | 1.904E-03 | ALOX15, CDK9, FABP4, FLT3, GSK3B, HIF1A, MAPK1, NFKB1 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.530E-05 | 1.904E-03 | CYP1B1, GLA, HIF1A, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.630E-05 | 1.994E-03 | ALOX12, ALOX15, ALOX5 |
| MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 1.630E-05 | 1.994E-03 | CDK8, CDK9, MAPK1 |
| BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 1.907E-05 | 2.270E-03 | ALOX5, FABP5, GAA, GLA, MAPK1, MMP9, NFKB1, TLR2, TTR |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.975E-05 | 2.324E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 2.309E-05 | 2.632E-03 | AKR1B1, CYP1B1, MAPK1, MMP9, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.529E-05 | 2.810E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 2.937E-05 | 3.105E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.937E-05 | 3.105E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.937E-05 | 3.105E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.937E-05 | 3.105E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.937E-05 | 3.105E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.827E-05 | 3.876E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 4.686E-05 | 4.617E-03 | ADRA2B, AKR1B1, ALOX15, APP, CYP1B1, FLT3, MAPK1, NOX4, PPARD, TLR2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.073E-05 | 4.888E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0048660; regulation of smooth muscle cell proliferation | 5.221E-05 | 5.008E-03 | AKR1B1, MMP2, MMP9, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 5.862E-05 | 5.432E-03 | TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 5.862E-05 | 5.432E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.862E-05 | 5.432E-03 | CYP1A1, CYP1A2 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 6.302E-05 | 5.790E-03 | CD38, HIF1A, NR1H4, PPARD |
| BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 6.393E-05 | 5.849E-03 | APP, CA2, CD38, HCAR2, HIF1A, MAPK1, MMP12, MMP2, NFKB1, NR1H4, TLR2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0051240; positive regulation of multicellular organismal process | 6.492E-05 | 5.902E-03 | ADRA2B, ALOX12, APP, CA2, CD38, CDK9, CYP1B1, HCAR2, HIF1A, MMP12, MMP9, NFKB1, NR1H4, PARP1, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 6.547E-05 | 5.902E-03 | CA2, CD38, FLT3, NPC1, PARP1, TLR2 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 6.559E-05 | 5.902E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 6.759E-05 | 6.032E-03 | AKR1B1, CD38, FABP3, MMP2, NR1H4, TLR2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 7.398E-05 | 6.470E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 8.002E-05 | 6.942E-03 | AKR1B1, ALOX15, APP, CA2, CYP1A1, CYP1A2, CYP1B1, FABP5, FLT3, GAA, GSK3B, HIF1A, LMNA, MAPK1, MMP9, POLB, PPARA, PPARD, SMN1, SMN2, TLR2, TP53, TSHR |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 8.304E-05 | 7.119E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 8.304E-05 | 7.119E-03 | APP, GSK3B, PARP1 |
| BP | GO:0008152; metabolic process | GO:0006091; generation of precursor metabolites and energy | 8.821E-05 | 7.474E-03 | AKR1B1, CYP1A2, GAA, GSK3B, NOX4, PPARD, XDH |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.154E-05 | 7.696E-03 | AKR1B1, ALOX12, CD38, FLT3, HIF1A, MAPK1, MMP12, MMP2, MMP9, PPARD, TSHR |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.750E-05 | 8.042E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.750E-05 | 8.042E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.025E-04 | 8.361E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0042572; retinol metabolic process | 1.145E-04 | 9.166E-03 | ALDH1A1, CYP1B1, TTR |
| BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 1.249E-04 | 9.878E-03 | HIF1A, MMP12, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.252E-04 | 9.878E-03 | ABCG2, APP, CD38, FLT3, GLA, MAPK1, MMP9, NFKB1, PARP1, RAB9A, SMN1, SMN2, TP53, TTR, XDH |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.265E-04 | 9.942E-03 | CYP1A2, MAPK1, MMP9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.538E-12 | 1.297E-09 | CA12; CA3; CA2; CA4; CA7; CA9 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.728E-09 | 1.486E-07 | CYP2C9; APP; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.506E-08 | 1.437E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 6.458E-08 | 2.777E-06 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.264E-06 | 3.625E-05 | CYP2C9; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.830E-07 | 6.294E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.045E-06 | 5.166E-05 | GSK3B; FLT3; MMP2; MAPK1; HIF1A; TP53; MMP9; NFKB1; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.304E-06 | 5.166E-05 | MAOA; GAA; ALOX15; AKR1B1; ALOX12; CYP2C19; CYP3A4; HSD17B10; CYP2C9; ALOX5; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.603E-06 | 3.938E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.160E-06 | 4.645E-05 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.860E-06 | 5.166E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.543E-05 | 3.809E-04 | MMP2; MAPK1; TP53; HIF1A; MMP9; TLR2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.592E-06 | 9.448E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.741E-05 | 3.367E-04 | FLT3; MAPK1; NFKB1; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.288E-06 | 9.642E-05 | MMP2; MAPK1; MMP9; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.793E-05 | 5.564E-04 | PARP1; LMNA; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.322E-05 | 5.085E-04 | GSK3B; MAPK1; PPARA; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 5.918E-05 | 5.358E-04 | GSK3B; RAB9A; TP53; NFKB1; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.199E-05 | 5.085E-04 | FLT3; MAPK1; TP53; HIF1A |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 8.287E-05 | 6.479E-04 | MAPK1; TP53; MMP9; NFKB1; TLR2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.937E-05 | 3.368E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.575E-04 | 1.084E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.531E-05 | 5.564E-04 | CA2; NR1H4; CYP3A4; ABCG2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.511E-04 | 2.237E-03 | HCAR2; MAPK1; PPARA; NFKB1; TSHR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.210E-04 | 1.462E-03 | CDK9; FLT3; TP53; MMP9; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.636E-04 | 2.739E-03 | ALOX5; MAPK1; NFKB1; TLR2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.636E-04 | 2.739E-03 | GSK3B; MAPK1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.940E-04 | 2.741E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.106E-03 | 9.057E-03 | CYP1B1; MAPK1; TP53; MMP9; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.727E-03 | 7.617E-03 | APP; GSK3B; MAPK1; HSD17B10 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.386E-03 | 6.529E-03 | GSK3B; MAPK1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.077E-03 | 5.451E-03 | MAPK1; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.363E-03 | 1.355E-02 | GSK3B; CD38; TP53; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.983E-04 | 4.682E-03 | GSK3B; MAPK1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.442E-03 | 6.529E-03 | MAPK1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.442E-03 | 6.529E-03 | GSK3B; MAPK1; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.778E-04 | 2.739E-03 | ALOX5; CYP1A1; CYP1B1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.364E-04 | 2.883E-03 | GSK3B; MAPK1; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.812E-03 | 1.359E-02 | GSK3B; MAPK1; TP53; NFKB1; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.545E-03 | 1.355E-02 | POLB; MAPK1; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.638E-03 | 1.359E-02 | MMP2; MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.442E-03 | 6.529E-03 | MAPK1; NFKB1; TLR2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.439E-03 | 1.355E-02 | MMP2; MAPK1; MMP9 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.845E-03 | 1.359E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.167E-03 | 1.405E-02 | MAPK1; NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.950E-03 | 1.359E-02 | MAPK1; NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.950E-03 | 1.359E-02 | GSK3B; MAPK1; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.034E-04 | 7.407E-04 | GAA; AKR1B1; GLA |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.505E-03 | 1.472E-02 | GSK3B; PPARA; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.942E-03 | 2.397E-02 | POLB; GSK3B; TP53; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.622E-03 | 1.472E-02 | MAPK1; MMP9; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.886E-03 | 1.841E-02 | MAPK1; TP53; NFKB1 |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 6.302E-03 | 1.936E-02 | NPC1; GAA; GLA |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.340E-03 | 2.723E-02 | GSK3B; TP53; PPARD |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.103E-02 | 3.110E-02 | GSK3B; PPARA; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.636E-02 | 4.020E-02 | GSK3B; MAPK1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.711E-02 | 4.025E-02 | MAPK1; NFKB1; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.893E-02 | 4.342E-02 | TP53; NFKB1; TLR2 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.947E-02 | 4.350E-02 | GSK3B; MAPK1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.683E-02 | 4.020E-02 | MAPK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.268E-02 | 3.355E-02 | FABP4; TSHR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.446E-02 | 3.657E-02 | MAPK1; HIF1A |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.268E-02 | 3.355E-02 | MAPK1; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.987E-02 | 4.382E-02 | MAPK1; TP53 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.935E-02 | 4.350E-02 | PPARA; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.732E-02 | 4.025E-02 | MAPK1; HIF1A |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.202E-02 | 4.794E-02 | MAPK1; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.225E-02 | 3.344E-02 | NFKB1; TLR2 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.683E-02 | 4.020E-02 | NFKB1; TLR2 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.683E-02 | 4.020E-02 | MAPK1; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.400E-02 | 3.595E-02 | AKR1B1; GLA |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.225E-02 | 3.344E-02 | GSK3B; TP53 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.311E-02 | 3.417E-02 | MAPK1; NFKB1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 9.814E-03 | 2.813E-02 | MAOA; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.523E-03 | 1.355E-02 | MAPK1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 8.688E-03 | 2.577E-02 | CYP3A4; XDH |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.546E-03 | 1.472E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.221E-03 | 9.319E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.097E-05 | 6.803E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAOA; APP |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Cancer | C00-C96 | GSK3B; HIF1A; TP53; FLT3; FLT3; CA9; MAPK1; MMP9; NFKB1; TLR2; PARP1; MMP2; APP; CD38 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; HCAR2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MAPK1; MMP9; TLR2; MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD; MMP12; HCAR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PPARD; HCAR2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; PARP1 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HCAR2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1; MMP2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| NA: NA | Dyslipidemia | NA | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MMP12 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |